Yoav Messinger

Summary

Affiliation: Children's Hospitals and Clinics of Minnesota
Country: USA

Publications

  1. ncbi Renal outcome of neonatal renal venous thrombosis: review of 28 patients and effectiveness of fibrinolytics and heparin in 10 patients
    Yoav Messinger
    Children s Hospitals and Clinics of Minnesota, St Paul, Minnesota, USA
    Pediatrics 118:e1478-84. 2006
  2. ncbi Pediatric acute lymphoblastic leukemia with a t(8;14)(q11.2;q32): B-cell disease with a high proportion of Down syndrome: a Children's Oncology Group study
    Yoav H Messinger
    Children s Hospitals and Clinics of Minnesota, Minneapolis, MN, USA
    Cancer Genet 205:453-8. 2012
  3. ncbi Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
    Yoav H Messinger
    Pediatric Hematologyand Oncology, Children s Hospitals and Clinics of Minnesota, 2525 Chicago Ave S, Minneapolis, MN 55404, USA
    Blood 120:285-90. 2012
  4. ncbi Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
    Yoav H Messinger
    Pediatric Hematology Oncology, Children s Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, USA
    Genet Med 14:135-42. 2012
  5. ncbi Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium
    Yoav Messinger
    Pediatric Hematology and Oncology, Children s Hospitals and Clinics of Minnesota, St Paul, Minnesota 55102, USA
    Pediatr Blood Cancer 55:254-9. 2010
  6. ncbi Type I pleuropulmonary blastoma: a report from the International Pleuropulmonary Blastoma Registry
    John R Priest
    International Pleuropulmonary Blastoma Registry, Children s Hospitals and Clinics of Minnesota, St Paul, Minnesota 55102, USA
    J Clin Oncol 24:4492-8. 2006

Collaborators

Detail Information

Publications6

  1. ncbi Renal outcome of neonatal renal venous thrombosis: review of 28 patients and effectiveness of fibrinolytics and heparin in 10 patients
    Yoav Messinger
    Children s Hospitals and Clinics of Minnesota, St Paul, Minnesota, USA
    Pediatrics 118:e1478-84. 2006
    ..PATIENTS, INTERVENTIONS, AND OUTCOME MEASURES: Twenty-eight newborns with renal venous thrombosis were treated at Children's Hospitals and Clinics of Minnesota and Fairview University Medical Center from 1991 to 2001...
  2. ncbi Pediatric acute lymphoblastic leukemia with a t(8;14)(q11.2;q32): B-cell disease with a high proportion of Down syndrome: a Children's Oncology Group study
    Yoav H Messinger
    Children s Hospitals and Clinics of Minnesota, Minneapolis, MN, USA
    Cancer Genet 205:453-8. 2012
    ..Children with DS and the t(8;14)(q11.2;q34) have improved EFS using standard COG therapy compared to non-DS patients. We did not find an increased number of patients with a concomitant Philadelphia chromosome in this population...
  3. ncbi Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
    Yoav H Messinger
    Pediatric Hematologyand Oncology, Children s Hospitals and Clinics of Minnesota, 2525 Chicago Ave S, Minneapolis, MN 55404, USA
    Blood 120:285-90. 2012
    ..Bortezomib merits further evaluation in combination therapy in pediatric B-precursor ALL. This study is registered at http://www.clinicaltrials.gov as NCT00440726...
  4. ncbi Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
    Yoav H Messinger
    Pediatric Hematology Oncology, Children s Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, USA
    Genet Med 14:135-42. 2012
    ..Cross-reactive immunologic material negative (CRIM-negative) Pompe patients develop high-titer antibody to the rhGAA and do poorly. We describe successful tolerance induction in CRIM-negative patients...
  5. ncbi Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium
    Yoav Messinger
    Pediatric Hematology and Oncology, Children s Hospitals and Clinics of Minnesota, St Paul, Minnesota 55102, USA
    Pediatr Blood Cancer 55:254-9. 2010
    ..Bortezomib is a proteasome inhibitor with in vitro synergy with corticosteroids and clinical activity in human lymphoid malignancies...
  6. ncbi Type I pleuropulmonary blastoma: a report from the International Pleuropulmonary Blastoma Registry
    John R Priest
    International Pleuropulmonary Blastoma Registry, Children s Hospitals and Clinics of Minnesota, St Paul, Minnesota 55102, USA
    J Clin Oncol 24:4492-8. 2006
    ..This article describes the first collection of type I PPB cases, analyzes outcome based on treatments of surgery or surgery plus chemotherapy, and presents type I PPB management recommendations...